Lupin’s arm receives FDA approval for Generic GIumetza extended-release Tablets

22 Jul 2013 Evaluate

Pharma major Lupin‘s U.S. subsidiary- Lupin Pharmaceuticals, Inc. has received final approval for its Metformin Hydrochloride extended release tablets (HCL ER) 500 mg and 1000 mg from the United States Food and Drugs Administration (FDA). According to IMS health data, the total sales of Glumetza HCL ER tablets, 500 mg and 1000 mg in US, for the twelve months ending March, 2013, was approximately $144 million.

Lupin's Metformin HCL ER Tablets, 500 mg and 1000 mg strengths are the AB-rated' generic equivalent of  Santarus, inc’s  Glumetz HCL ER Tablets, 500 mg and 1000 me strengths. Lupin had earlier received the tentative approval for generic GLUMETZA (Metformin Hydrochloride Extended Release Tablets) 1000 mg and 500 mg from the United States Food and Drugs Administration (FDA) in January, 2012.

Metformin HCL ER tablets are biguanide and indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Lupin believes that it is the first applicant to file an ANDA for Glumetza HCL ER Tablets, 500 mg & 1000 mg strengths and as such will be entitled to 180 days of marketing exclusivity.

Lupin Share Price

2114.10 33.75 (1.62%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×